Christophe Massard

Research interests

Publications

• Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

  The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00275-9

• The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

  Nature Cancer · 2022 · https://doi.org/10.1038/s43018-022-00332-x

• Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00580-8

• Impact of COVID-19 on healthcare organisation and cancer outcomes

  European Journal of Cancer · 2021 · https://doi.org/10.1016/j.ejca.2021.05.012

• Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

  JAMA Oncology · 2019 · https://doi.org/10.1001/jamaoncol.2019.1022

• Hyperprogressive disease: recognizing a novel pattern to improve patient management

  Nature Reviews Clinical Oncology · 2018 · https://doi.org/10.1038/s41571-018-0111-2

• Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

  Clinical Cancer Research · 2018 · https://doi.org/10.1158/1078-0432.ccr-18-0981

• Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy232

• Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2018.78.2292

• A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30413-3

• High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

  Cancer Discovery · 2017 · https://doi.org/10.1158/2159-8290.cd-16-1396

• First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

  Clinical Cancer Research · 2017 · https://doi.org/10.1158/1078-0432.ccr-17-1588

• Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis

  PLoS Medicine · 2016 · https://doi.org/10.1371/journal.pmed.1002201

• Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

  Clinical Cancer Research · 2016 · https://doi.org/10.1158/1078-0432.ccr-16-1741

• Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2015.63.7421

• Immune-related adverse events with immune checkpoint blockade: a comprehensive review

  European Journal of Cancer · 2016 · https://doi.org/10.1016/j.ejca.2015.11.016

• Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer

  European Urology · 2014 · https://doi.org/10.1016/j.eururo.2014.10.001

• Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

  Annals of Oncology · 2013 · https://doi.org/10.1093/annonc/mdt136

• A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas

  British Journal of Cancer · 2011 · https://doi.org/10.1038/bjc.2011.294

Current projects

No projects listed.